within Pharmacolibrary.Drugs.ATC.G;

model G04BE07_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0011833333333333333,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.062,
    k12             = 59,
    k21             = 59
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04BE07_1</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Apomorphine is a non-ergoline dopamine agonist used primarily in the treatment of motor fluctuations ('off' episodes) in Parkinson's disease. It is administered as a rescue medication for rapid symptom relief. It is approved for subcutaneous use and is not typically administered orally due to extensive first-pass metabolism and very low oral bioavailability.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in patients with Parkinson's disease (mean 65 years), multiple subcutaneous doses (5-10 mg).</p><h4>References</h4><ol><li><p>Agbo, F, et al., &amp; Navia, B (2021). Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson&#x27;s Disease and &quot;OFF&quot; Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. <i>Neurology and therapy</i> 10(2) 693–709. DOI:<a href=&quot;https://doi.org/10.1007/s40120-021-00251-6&quot;>10.1007/s40120-021-00251-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33991326/&quot;>https://pubmed.ncbi.nlm.nih.gov/33991326</a></p></li><li><p>Sam, E, et al., &amp; Verbeke, N (1995). Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. <i>European journal of drug metabolism and pharmacokinetics</i> 20(1) 27–33. DOI:<a href=&quot;https://doi.org/10.1007/BF03192285&quot;>10.1007/BF03192285</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7588990/&quot;>https://pubmed.ncbi.nlm.nih.gov/7588990</a></p></li><li><p>Ramot, Y, et al., &amp; Yacobi-Zeevi, O (2018). ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability. <i>CNS drugs</i> 32(5) 443–454. DOI:<a href=&quot;https://doi.org/10.1007/s40263-018-0512-x&quot;>10.1007/s40263-018-0512-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29637529/&quot;>https://pubmed.ncbi.nlm.nih.gov/29637529</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04BE07_1;
